Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Amazon Secures 200 MW Wind Power Deals in Sweden 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Toyota Global Sales Fall as China Demand Slumps 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Add as a preferred source on Google
EDEN PRAIRIE, Minn., April 12, 2018 -- CHF Solutions, Inc. (Nasdaq:CHFS) announced today its commercial expansion into the Hong Kong market through its Asia distributor, Transmedic. Further, Transmedic has confirmed its first commercial orders for both Singapore and Hong Kong.
"Our expansion into the Asian markets is a key factor in our commercialization strategy, and our distribution partner, Transmedic, has flawlessly initiated on executing that strategy,” commented John Erb, chairman and chief executive officer of CHF Solutions. “We believe the heart failure market for patients suffering from fluid overload remains largely untapped in Asia and that the Aquadex FlexFlow system provides a clinically proven alternative therapy option over pharmacotherapy.”
These commercial orders were for both Aquadex FlexFlow consoles and the corresponding disposable products.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
[email protected]
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
[email protected]
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
[email protected]
